Lower plasma levels of glutamine have been observed in HCC patients due to the increased uptake by tumours via glutamine transporter ASCT2 upregulation in HCC cells (Sun et al., 2016), which has also been observed in PDAC (Wang VM. The gene discussed is SLC1A5; the disease is neoplasm.